
|Articles|June 11, 2014
- June 2014
- Volume 18
- Issue 1
Cyclosporine Treats Severe Poison Ivy in Case Study
Advertisement
In a case study presented at the American Academy of Allergy Asthma and Immunology Annual Meeting, researchers successfully treated a 33-year-old patient with yearly, unavoidable poision ivy exposure without using steroids.
Instead, researchers used a 200-mg/day cyclosporine regimen during the patient's exposure period, which resulted in a resolution of poison ivy symptoms after 6 weeks of therapy. The dose was also decreased to 100 mg every other day without the poison ivy symptoms returning, and without the need for topical or systemic corticosteroids.
Articles in this issue
over 12 years ago
Consuming Antioxidants and Fish May Prevent Macular Degenerationover 12 years ago
Test May Aid Diagnosis of Fungal Nail Infectionover 12 years ago
18 Years Strong!over 12 years ago
Pharmacy Times: Leading the Wayover 12 years ago
Odd Allergies: OTC Answers?over 12 years ago
Vitamin D Supplements: Reaping the Benefits from the Right Amountover 12 years ago
Teens Frequently Given Opioids for Headacheover 12 years ago
For Plaque Removal, Straight Toothbrush Beats Angledover 12 years ago
Aspirin May Reduce Ovarian Cancer RiskAdvertisement
Related to this article

Professional membership and experienced mentor leadership offer new pharmacy technicians a dual advantage, serving as a comprehensive training accelerator.

A biologic stewardship framework can enhance consistency, safety, and sustainability of biologic use in health systems.

Artificial intelligence (AI) transforms a chaotic, reactive process into an adaptive, proactive system that improves workflow and patient safety.

Pharmacists are well equipped to manage DOAC therapy by providing initial education, adherence support, and safety monitoring.

Pharmacists play a key role in guiding age- and risk-based vaccination decisions to protect against invasive and noninvasive disease.

Peer Reviewed
Gepotidacin and zoliflodacin show comparable efficacy to standard care for urogenital gonorrhea, offering promising alternatives given the recent rise in antimicrobial resistance.

With nearly 8 in 10 older adults misusing at least 1 OTC product, clearer counseling and labels could close the gap.
Advertisement
Advertisement
Trending on Pharmacy Times
1
Adult Pneumococcal Immunizations: A Practical Guide for Pharmacists
2
FDA Approves Rebisufligene Etisparvovec as First Gene Therapy for Children With Sanfilippo Syndrome Type A
3
FDA Reduces Monitoring Time for First Two Tarlatamab Doses
4
How Pharmacists Overcome PCSK9 Inhibitor Access Barriers
5

